Skip to content
BioSupply Trends Quarterly logo
  • About Us
  • About Us
Subscribe
  • News
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Clinical Trials
    • COVID
    • Dermatology
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Mental Health
    • Therapeutics
    • Vaccines
    • Washington Report
    • Women’s Disorders
  • Industry Insight
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Chronic Illness
    • COVID
    • Dermatology
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Mental Health
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
    • Women’s Disorders
  • Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • News
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Clinical Trials
    • COVID
    • Dermatology
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Mental Health
    • Therapeutics
    • Vaccines
    • Washington Report
    • Women’s Disorders
  • Industry Insight
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Chronic Illness
    • COVID
    • Dermatology
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Mental Health
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
    • Women’s Disorders
  • Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Home
  • News
    • All News
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Clinical Trials
    • COVID
    • Dermatology
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Mental Health
    • Therapeutics
    • Vaccines
    • Washington Report
    • Women’s Disorders
  • Industry Insight
    • All Industry Insight
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Chronic Illness
    • COVID
    • Dermatology
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Mental Health
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
    • Women’s Disorders
  • Operations & Management
    • All Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • All Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Subscribe
  • About Us
  • Home
  • News
    • All News
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Clinical Trials
    • COVID
    • Dermatology
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Mental Health
    • Therapeutics
    • Vaccines
    • Washington Report
    • Women’s Disorders
  • Industry Insight
    • All Industry Insight
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Chronic Illness
    • COVID
    • Dermatology
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Mental Health
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
    • Women’s Disorders
  • Operations & Management
    • All Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • All Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Subscribe
  • About Us
BioSupply Trends Quarterly logo

COVID-19 Vaccine Tied to Increased Survival in Patients with Cancer

A study has found that for patients with certain types of advanced lung or skin cancer, administration of a SARS-CoV-2 mRNA vaccine within 100 days of starting immune checkpoint inhibitors is associated with increased overall survival.

RSV Poses Significant Threat to Patients with Systemic Autoimmune Rheumatic Diseases

A retrospective cohort study has found respiratory syncytial virus infections are associated with substantial morbidity among patients with systemic autoimmune rheumatic diseases, with more than half of infected individuals requiring hospitalization. 

Study Finds Viral Infections Increase Risk of Heart Attack/Stroke

A new study has found people have an increased risk of major cardiovascular events following viral infections such as SARS-CoV-2, influenza, HIV, hepatitis C and varicella zoster virus. 

Study Shows Hormone Therapy Is Linked to Autoimmune Disease

A recent study shows the use of hormone therapy in postmenopausal women was associated with a significantly higher incidence and risk of autoimmune diseases. 

Takeda’s HyHub and HyHub Duo Devices Now Available in the U.S.

The HyHub and HyHub Duo devices are now available in the U.S. for patients 17 years of age and older who are prescribed HYQVIA.

Grifols Withdraws Four Lots of Gamunex-C 10%

Grifols Therapeutics has initiated a voluntary withdrawal of four lots of Gamunex-C 10%.

FDA Accepts NDA for Leniolisib to Treat Children with APDS

FDA has accepted a supplemental new drug application for leniolisib to treat activated phosphoinositide 3-kinase delta syndrome, or APDS, in children aged 4 to 11 years.

COVID mRNA Vaccine Induces Immune Response Against Cancer

New research has found that patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine. 

FDA Approves Libtayo for Cutaneous Squamous Call Carcinoma

The U.S. Food and Drug Administration has approved Libtayo (cemiplimab-rwlc) for the adjuvant, or postsurgical, treatment of adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.

Study Finds Possible Link Between Chronic Pain and Eosinophilia

A small study of medical records unexpectedly found that 12 percent of chronic pain patients who were treated with spinal cord stimulation or an implanted pain medicine pump had a white blood cell condition called eosinophilia.

← Previous
Next →
BioSupply Trends Quarterly logo
FFF Enterprises logo
  • Current Issue
  • Past Issues
  • Resources
  • Current Issue
  • Past Issues
  • Resources
  • About BSTQ
  • Subscribe to BSTQ
  • eNewsletter Opt-in
  • Contact Us
  • About BSTQ
  • Subscribe to BSTQ
  • eNewsletter Opt-in
  • Contact Us
  • Advertiser Information
  • Media Kit
  • Editorial Calendar
  • Editorial Guidelines
  • Advertiser Information
  • Media Kit
  • Editorial Calendar
  • Editorial Guidelines
Facebook-f Linkedin-in

FFF Enterprises.com | Privacy Statement | Terms of Use | California Consumer Privacy Act (CCPA) Opt-Out Icon

FFF Enterprises.com
Privacy Statement
Terms of Use
California Consumer Privacy Act (CCPA) Opt-Out Icon

©2024 FFF Enterprises, Inc. All Rights Reserved. Property of FFF Enterprises, Inc.

The information provided on this website is not medical advice, nor is it intended to be a substitute for medical advice, diagnosis, and treatment. Always seek the advice of a physician or other qualified health provider with questions concerning a medical condition. Never disregard professional medical advice, or delay seeking it based on information provided on this website.